報價延遲最少15分鐘:2026/04/21 22:31 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.81 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.35/-0.94
|
|
企業價值
810.64M
|
| 資產負債 |
|
每股賬面淨值
0.67
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
4.63M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations,acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need. |
